You just read:

Avillion Announces US Approval of Pfizer's BOSULIF® (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)

News provided by

Avillion LLP

Dec 19, 2017, 15:35 ET